Fellowship · Philadelphia, PA
Sponsored by University of Pennsylvania Health System
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
The Lancet. Neurology · 2021 · 608 citations · Chafic Karam
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Frontiers in neurology · 2023 · 78 citations · Chafic Karam
Trial of Intravenous Immune Globulin in Dermatomyositis.
The New England journal of medicine · 2022 · 163 citations · Chafic Karam
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2025 · 35 citations · Chafic Karam
Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
Heart failure reviews · 2022 · 94 citations · Chafic Karam
Gene therapy for ALS: A review.
Molecular therapy : the journal of the American Society of Gene Therapy · 2021 · 144 citations ·
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve · 2021 · 141 citations · Chafic Karam, Colin Quinn
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
Muscle & nerve · 2024 · 35 citations · Shawn Bird, Paul McIntosh, Colin Quinn, Chafic Karam